BALEKAFUSP ALFA
UNII K6TVH24GM3

Substance Identification & Data

This profile provides standardized clinical and technical data for Balekafusp Alfa, uniquely identified by the FDA Unique Ingredient Identifier (UNII) K6TVH24GM3.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2866185-77-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
K6TVH24GM3
CAS Registry Number
2866185-77-3
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
BALEKAFUSP ALFA
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C216070
National Cancer Institute reference terminology for clinical and research data.
INN ID
13040
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Balekafusp alfa
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Balekafusp Alfa. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Balekafusp alfa

Common Names & Synonyms

Immunoglobulin G1 [301-alanine], anti-(human interleukin 2) (human-Mus musculus monoclonal ANV419 γ1-chain), disulfide with human-Mus musculus monoclonal ANV419 κ-chain N-terminal fragment fusion protein with peptide linker (GGG) fusion protein with (77-133)-(2-76)-interleukin 2 [125-serine] (human) fusion protein with peptide linker (GGGG) fusion protein with human-Mus musculus monoclonal ANV419 κ-chain C-terminal fragment, dimer
balekafusp alfa [INN]
gamma 1 heavy chain (1-451) [VH (Homo sapiens IGHV5-51*01 -(IGHD) -IGHJ3*01, CDR-Kabat [5.17.12] (31-35.50-66.99-110)) (1-121) -Homo sapiens IGHG1*03 (CH1 (122-219), hinge (220-234), CH2 N><sup>301</sup>A (235-344), CH3 (345-449), CHS (450-451)) (122-451)]-disulfide with partial kappa light chain fused to a circular permuted form of human interleukin-2 (1'-355') [partial V-KAPPA (Homo sapiens IGKV1-39*01, CDR-Kabat [8] (partial CDR-L1: Kabat L.24-L.27D) (24'-31')) (1'-31')] fused via peptide linker <sup>32'</sup>GGG<sup>34'</sup> to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) in a permuted form (C-terminal fragment 77-133 (35'-91' in the current sequence) fused to the N-terminal fragment 2-76 (92'-166' in the current sequence)), variant (<sup>125</sup>C><sup>S83'</sup>), fused via peptide linker <sup>167'</sup>GGGG<sup>170'</sup> to a partial kappa light chain [V-KAPPA (Homo sapiens IGKV1-39*01 -IGKJ4*01, CDRKabat [5.7.9] (partial CDR-L1: Kabat L.30-L.34) (171'-175'.191'-197'.230'-238')) (171'-248') -Homo sapiens IGKC*01 (249'-355')]; dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
humanized immunoglobulin G1-kappa, anti-[human interleukin-2 (IL-2, T-cell growth factor, TCGF)] with an engineered kappa light chain, where a circular permuted form of human interleukin-2 is inserted within CDR-L1 between Y<sup>31</sup>(Kabat L.27D) and D<sup>34</sup> (Kabat L.30), Q<sup>32</sup>>del (Kabat L.28), G<sup>33</sup>>del (Kabat L.29) through sup>32</sup>GGG<sup>34</sup> and 167GGGG170 linkers

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus